Treatment of Parkinson's disease (PD), either as monotherapy (without levodopa) or in combination with L-DOPA therapy, in the early stages of the disease as well as in the advanced ones
Treatment of gait disorders associated with Parkinson's disease (no related cause) and other forms of parkinsonism
Other uses
The drug has been shown to enhance working memory capacities in normal aging adults.[4]
In age-related memory impairment, it has a positive effect on psychophysiological state of elderly people, improving memory and attention and increasing the velocity of psychomotor reactions and lability of nervous processes.[5]
It enhances cognitive skill learning in healthy older adults.[6]
Another rare side effect of piribedil is excessive daytime sleepiness and unintended sleep episodes.[9][10]
Overdose
At very high doses, piribedil has an emetic action on the chemoreceptor trigger zone (CTZ). Tablets will thus be rapidly rejected, which explains why no data are currently available concerning the risk of overdosage.[medical citation needed]
^Gobert A, Di Cara B, Cistarelli L, Millan MJ (April 2003). "Piribedil enhances frontocortical and hippocampal release of acetylcholine in freely moving rats by blockade of alpha 2A-adrenoceptors: a dialysis comparison to talipexole and quinelorane in the absence of acetylcholinesterase inhibitors". The Journal of Pharmacology and Experimental Therapeutics. 305 (1): 338–346. doi:10.1124/jpet.102.046383. PMID12649387. S2CID29234876.
^Gierski F, Peretti CS, Ergis AM (January 2007). "Effects of the dopamine agonist piribedil on prefrontal temporal cortical network function in normal aging as assessed by verbal fluency". Progress in Neuro-Psychopharmacology & Biological Psychiatry. 31 (1): 262–268. doi:10.1016/j.pnpbp.2006.06.017. PMID16876301. S2CID792757.
^Bochkarev VK, Faĭzulloev AZ, Avedisova AS (2005). "[Efficacy of pronoran in age-related memory impairment]". Zhurnal Nevrologii I Psikhiatrii Imeni S.S. Korsakova. 105 (2): 46–50. PMID15792142.
^Peretti CS, Gierski F, Harrois S (November 2004). "Cognitive skill learning in healthy older adults after 2 months of double-blind treatment with piribedil". Psychopharmacology. 176 (2): 175–181. doi:10.1007/s00213-004-1869-8. PMID15138753. S2CID24952829.
^Tschopp L, Salazar Z, Gomez Botello MT, Roca CU, Micheli F (2010). "Impulse control disorder and piribedil: report of 5 cases". Clinical Neuropharmacology. 33 (1): 11–13. doi:10.1097/WNF.0b013e3181c4ae2e. PMID19959959. S2CID30844295.
^ abTRIVASTAL Retard 50 (piribedil) Prescribing Information, Servier Laboratories, April 2008. [1]Archived 19 December 2012 at the Wayback Machine
^Gouraud A, Millaret A, Descotes J, Vial T (2011). "Piribedil-induced sleep attacks in patients without Parkinson disease: a case series". Clinical Neuropharmacology. 34 (3): 104–107. doi:10.1097/WNF.0b013e31821f0d8b. PMID21586915. S2CID22169346.
^Nagaraja D, Jayashree S (September 2001). "Randomized study of the dopamine receptor agonist piribedil in the treatment of mild cognitive impairment". The American Journal of Psychiatry. 158 (9): 1517–9. doi:10.1176/appi.ajp.158.9.1517. PMID11532743.
^Newman-Tancredi A, Cussac D, Audinot V, Nicolas JP, De Ceuninck F, Boutin JA, Millan MJ (November 2002). "Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. II. Agonist and antagonist properties at subtypes of dopamine D(2)-like receptor and alpha(1)/alpha(2)-adrenoceptor". The Journal of Pharmacology and Experimental Therapeutics. 303 (2): 805–814. doi:10.1124/jpet.102.039875. PMID12388667. S2CID35238120.
^ abSchubert-Zsilavecz M. "Piribedil". Neue Arzneimittel 2008 (in German).